Melinta acquires antibiotics business | December 4, 2017 Issue - Vol. 95 Issue 48 | Chemical & Engineering News
Volume 95 Issue 48 | p. 15 | Concentrates
Issue Date: December 4, 2017

Melinta acquires antibiotics business

Department: Business
Keywords: Mergers & acquisitions, antibiotics, Melinta

Melinta Therapeutics is buying the Medicines Co.’s portfolio of infectious disease drugs in a deal worth at least $270 million. Melinta gains three marketed drugs—Orbactiv, Minocin IV, and the new urinary tract infection drug combination Vabomere—that it says will complement its own recently approved Baxdela. The Medicines Co. got Vabomere through its 2013 acquisition of Rempex Pharmaceuticals. It acquired Orbactiv, which passed through several hands after being discovered at Eli Lilly & Co., in 2009.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment